Dataset Information
Efficacy and safety of programmed death-1 inhibitors combined with chemotherapy in patients with advanced gastric cancer.
Ontology highlight
ABSTRACT:
SUBMITTER: Cheng X
PROVIDER: S-EPMC12369166 | biostudies-literature | 2025 Aug
REPOSITORIES: biostudies-literature
Publications
Efficacy and safety of programmed death-1 inhibitors combined with chemotherapy in patients with advanced gastric cancer.
BMC gastroenterology 20250821 1
OBJECTIVE: Programmed death-1 (PD-1) inhibitors combined with chemotherapy show certain clinical benefits in advanced gastric cancer patients, but more evidence is still needed. The present study aimed to investigate the efficacy and safety of PD-1 inhibitors combined with chemotherapy in these patients. METHODS: Forty-three patients with advanced gastric cancer receiving PD-1 inhibitors (including camrelizumab, sintilimab, and tislelizumab, 200 mg every 3 weeks) combined with chemotherapy were ...[more]